首页> 外文期刊>Endocrinology >Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.
【24h】

Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4.

机译:外周和中央GLP-1受体群体介导外周给予GLP-1受体激动剂,利拉鲁肽和exendin-4的厌食作用。

获取原文
获取原文并翻译 | 示例
       

摘要

The long-acting glucagon-like peptide-1 receptor (GLP-1R) agonists, exendin-4 and liraglutide, suppress food intake and body weight. The mediating site(s) of action for the anorectic effects produced by peripheral administration of these GLP-1R agonists are not known. Experiments addressed whether food intake suppression after i.p. delivery of exendin-4 and liraglutide is mediated exclusively by peripheral GLP-1R or also involves direct central nervous system (CNS) GLP-1R activation. Results showed that CNS delivery [third intracerebroventricular (3(rd) ICV)] of the GLP-1R antagonist exendin-(9-39) (100 mug), attenuated the intake suppression by i.p. liraglutide (10 mug) and exendin-4 (3 mug), particularly at 6 h and 24 h. Control experiments show that these findings appear to be based neither on the GLP-1R antagonist acting as a nonspecific competing orexigenic signal nor on blockade of peripheral GLP-1R via efflux of exendin-(9-39) to the periphery. To assess the contribution of GLP-1R expressed on subdiaphragmatic vagal afferents to the anorectic effects of liraglutide and exendin-4, food intake was compared in rats with complete subdiaphragmatic vagal deafferentation and surgical controls after i.p. delivery of the agonists. Both liraglutide and exendin-4 suppressed food intake at 3 h, 6 h, and 24 h for controls; for subdiaphragmatic vagal deafferentation rats higher doses of the GLP-1R agonists were needed for significant food intake suppression, which was observed at 6 h and 24 h after liraglutide and at 24 h after exendin-4. Conclusion: Food intake suppression after peripheral administration of exendin-4 and liraglutide is mediated by activation of GLP-1R expressed on vagal afferents as well as direct CNS GLP-1R activation.
机译:长效胰高血糖素样肽1受体(GLP-1R)激动剂exendin-4和利拉鲁肽可抑制食物摄入和体重。由这些GLP-1R激动剂的外周给药产生的厌食作用的介导作用位点是未知的。实验探讨了腹腔注射后是否抑制食物摄入。 exendin-4和利拉鲁肽的递送仅由外周GLP-1R介导,或还涉及直接中枢神经系统(CNS)GLP-1R激活。结果显示,GLP-1R拮抗剂exendin-(9-39)(100杯)的CNS递送[第三脑室内(3(rd)ICV)]减轻了i.p.的摄入抑制。利拉鲁肽(10杯)和exendin-4(3杯),尤其是在6小时和24小时。对照实验表明,这些发现似乎既不是基于充当非特异性竞争性致病信号的GLP-1R拮抗剂,也不是基于通过exendin-(9-39)向周围的流出而阻断外周GLP-1R。为了评估在dia下迷走神经传入中表达的GLP-1R对利拉鲁肽和exendin-4的厌食作用的影响,比较了完全dia下迷走神经脱除咖啡因和手术后i.p.的大鼠的食物摄入。激动剂的交付。利拉鲁肽和exendin-4均在对照组的3、6、24小时抑制了食物的摄入。对于dia下迷走神经脱除迷走神经的大鼠,需要更大剂量的GLP-1R激动剂以显着抑制食物摄入,这在利拉鲁肽治疗后6小时和24小时以及exendin-4治疗后24小时观察到。结论:Exendin-4和利拉鲁肽外围给药后对食物摄入的抑制是由迷走神经传入表达的GLP-1R激活以及中枢神经系统GLP-1R的直接激活介导的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号